Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Fundacao Champalimaud clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Portugal, Germany, Italy, Poland and Israel registers with Fundacao Champalimaud as lead sponsor. Synced 12 Nov 2026
7Current trials
3Recruiting now
4Drugs in these trials
5Trial registers
At a glance

Fundacao Champalimaud is the lead sponsor of 7 current clinical trials in our Portugal, Germany, Italy, Poland and Israel registers. 3 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Carboplatin, Cyclophosphamide and Paclitaxel. The most-studied condition is Obsessive-Compulsive Disorder.

ClinicalTrials.gov trials by status

  • Recruiting343%
  • Not yet open229%
  • Active, closed229%

Trials by phase

  • Not applicable457%
  • Observational229%
  • Phase 2114%
01

Clinical trials sponsored by Fundacao Champalimaud

7 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
In Vivo Cortical Excitability Modulation in Major Depressive Disorder
NCT05441969 · ClinicalTrials.gov ↗ · Major Depressive Disorder
Observational Recruiting 2020-05 Portugal
Reinforcement Learning and Obsessive-compulsive Disorder: Exploring the Role of the Orbitofrontal Cortex
NCT06566781 · ClinicalTrials.gov ↗ · Obsessive-Compulsive Disorder
Observational Recruiting 2019-10 Portugal
Single-Dose Image-Guided Radiotherapy With Urethral Sparing and DIL Boost for Intermediate-Risk Prostate Cancer (PROSINT II)
NCT04035642 · ClinicalTrials.gov ↗ · Prostate Cancer
Not applicable Recruiting 2019-06 Portugal
Circuit-Guided Neuromodulation for Anorexia Nervosa
NCT07860320 · ClinicalTrials.gov ↗ · Anorexia Nervosa
Not applicable Not yet open 2026-09 Portugal
Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab
NCT06371807 · ClinicalTrials.gov ↗ · Early Breast Cancer, Triple Negative Breast Cancer
Phase 2 Not yet open 2024-07 Portugal
Comparing Decision on Aesthetics After Breast Cancer Locoregional Treatment.
NCT05196269 · ClinicalTrials.gov ↗ · Breast Cancer
Not applicable Active, closed 2023-08 Germany, Italy, Poland, Portugal, Israel
Improving Obsessive-compulsive Disorder Treatments: From Lesions to Neuromodulation Targets
NCT06490965 · ClinicalTrials.gov ↗ · Obsessive-Compulsive Disorder
Not applicable Active, closed 2024-11 Portugal

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Fundacao Champalimaud trials

4 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Fundacao Champalimaud trials

7 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in Portugal73
Clinical trials in Germany10
Clinical trials in Italy10
Clinical trials in Poland10
Clinical trials in Israel10

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Obsessive-Compulsive Disorder

SponsorTrials
Shanghai Mental Health Center4
Centre Hospitalier Henri Laborit2
Uppsala University Hospital2
Susanne Walitza1
National Institute of Mental Health, Czech Republic1
Ben-Gurion University of the Negev1

Sponsors with the most current trials registered for this condition.

06

Questions about Fundacao Champalimaud trials

How many clinical trials does Fundacao Champalimaud sponsor?

Fundacao Champalimaud is the lead sponsor of 7 current trials on ClinicalTrials.gov in our Portugal, Germany, Italy, Poland and Israel registers, as of the registry sync on 12 November 2026. Completed and withdrawn studies are not counted.

Are Fundacao Champalimaud trials recruiting?

Yes. 3 of its 7 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Fundacao Champalimaud testing?

Its current trials name 4 drugs and biologicals as interventions. The most frequent are Carboplatin (1), Cyclophosphamide (1), Paclitaxel (1) and Pembrolizumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 12 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.